{"filing":{"accession_number":"0001005286-26-000032","cik":"0001005286","ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"lfcr-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/lfcr-20260805.htm"},"events":[{"id":24359,"run_id":22061,"accession_number":"0001005286-26-000032","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"LifeCore Biomedical issued a press release announcing consolidated financial results for Q2 and six months ended June 30, 2026, disclosing revenue of $34.2 million, net loss of $6.2 million, and Adjusted EBITDA figures with period-over-period comparisons, along with reaffirmed 2026 guidance and an investor presentation.","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24872,"accession_number":"0001005286-26-000032","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing consolidated financial results for Q2 and six months ended June 30, 2026. The press release (Exhibit 99.1) provides detailed revenue, gross profit, operating expenses, net loss, and Adjusted EBITDA figures with period-over-period comparisons, along with forward guidance for 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing its consolidated financial results for the second quarter and six months ended June 30, 2026,\" which is the hallmark of an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:24:54.411619+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24873,"accession_number":"0001005286-26-000032","item_number":"7.01","item_title":"Regulation FD.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an investor presentation made available on August 5, 2026, but the supplemental exhibit EX-99.1 contains a full earnings release announcing Q2 2026 financial results for the period ended June 30, 2026, including revenue of $34.2 million, net loss of $6.2 million, and reaffirmed 2026 guidance. This is a standard quarterly earnings disclosure with detailed financial metrics and CEO commentary, meeting the definition of earnings_release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:24:54.411619+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24872,"accession_number":"0001005286-26-000032","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing consolidated financial results for Q2 and six months ended June 30, 2026. The press release (Exhibit 99.1) provides detailed revenue, gross profit, operating expenses, net loss, and Adjusted EBITDA figures with period-over-period comparisons, along with forward guidance for 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing its consolidated financial results for the second quarter and six months ended June 30, 2026,\" which is the hallmark of an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:24:54.411619+00:00","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-08-05"},{"id":24873,"accession_number":"0001005286-26-000032","item_number":"7.01","item_title":"Regulation FD.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an investor presentation made available on August 5, 2026, but the supplemental exhibit EX-99.1 contains a full earnings release announcing Q2 2026 financial results for the period ended June 30, 2026, including revenue of $34.2 million, net loss of $6.2 million, and reaffirmed 2026 guidance. This is a standard quarterly earnings disclosure with detailed financial metrics and CEO commentary, meeting the definition of earnings_release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:24:54.411619+00:00","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-08-05"}]}